drugset / Trial / NCT03367962
Detection of Graft Versus Host Disease With [18F]F-AraG
Phase 1
Completed
9 enrolled
CellSight Technologies, Inc.
National Cancer Institute (NCI) · collabStanford University · collab
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This is a single-center imaging study to determine utility of in vivo imaging with \[18F\]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy, and patients at high risk for developing acute GVHD. \[18F\]F-AraG PET scans will be compared to biopsy results to correlate T cell accumulation which is implicated in the disease. High risk patients will be followed to verify predictive potential of \[18F\]F-AraG.
Timeline
- Start
- 2018-05-15
- Primary completion
- 2023-06-21
- Completion
- 2023-10-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-ARAG | Diagnostic / imaging agent | 5 mbq | Intravenous |